BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henrion-Caude A, Flamant C, Roussey M, Housset C, Flahault A, Fryer AA, Chadelat K, Strange RC, Clement A. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 2002;36:913-7. [PMID: 12297838 DOI: 10.1053/jhep.2002.35534] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Henderson CJ, Wolf CR. Disruption of the Glutathione Transferase Pi Class Genes. Gluthione Transferases and Gamma-Glutamyl Transpeptidases. Elsevier; 2005. pp. 116-35. [DOI: 10.1016/s0076-6879(05)01007-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
2 de Lima Marson FA, Bertuzzo CS, Secolin R, Ribeiro AF, Ribeiro JD. Genetic interaction of GSH metabolic pathway genes in cystic fibrosis. BMC Med Genet 2013;14:60. [PMID: 23758905 DOI: 10.1186/1471-2350-14-60] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
3 Lamireau T, Monnereau S, Martin S, Marcotte J, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. Journal of Hepatology 2004;41:920-5. [DOI: 10.1016/j.jhep.2004.08.006] [Cited by in Crossref: 131] [Cited by in F6Publishing: 99] [Article Influence: 7.3] [Reference Citation Analysis]
4 Watts KD, Seshadri R, Sullivan C, McColley SA. Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatr Pulmonol 2009;44:594-601. [PMID: 19437506 DOI: 10.1002/ppul.21037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
5 Gallagher EP, Gardner JL, Barber DS. Several glutathione S-transferase isozymes that protect against oxidative injury are expressed in human liver mitochondria. Biochemical Pharmacology 2006;71:1619-28. [DOI: 10.1016/j.bcp.2006.02.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
6 Li L, Falany CN. Elevated hepatic SULT1E1 activity in mouse models of cystic fibrosis alters the regulation of estrogen responsive proteins. J Cyst Fibros 2007;6:23-30. [PMID: 16798114 DOI: 10.1016/j.jcf.2006.05.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
7 Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13:529-536. [PMID: 17901760 DOI: 10.1097/mcp.0b013e3282f10a16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
8 Büscher R, Grasemann H. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road? Naunyn Schmiedebergs Arch Pharmacol 2006;374:65-77. [PMID: 17033796 DOI: 10.1007/s00210-006-0101-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bao S, Zheng J, Shi G. The role of T helper 17 cells in the pathogenesis of hepatitis B virus-related liver cirrhosis (Review). Mol Med Rep 2017;16:3713-9. [PMID: 28731149 DOI: 10.3892/mmr.2017.7044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry: Pulmonary Function in Individuals with Cystic Fibrosis. Liver Transpl 2012;18:585-93. [DOI: 10.1002/lt.23389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
11 Tomaiuolo R, Degiorgio D, Coviello D, Baccarelli A, Elce A, Raia V, Motta V, Seia M, Castaldo G, Colombo C. An MBL2 haplotype and ABCB4 variants modulate the risk of liver disease in cystic fibrosis patients: A multicentre study. Digestive and Liver Disease 2009;41:817-22. [DOI: 10.1016/j.dld.2009.03.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
12 L'ecuyer T, Allebban Z, Thomas R, Vander Heide R. Glutathione S -transferase overexpression protects against anthracycline-induced H9C2 cell death. American Journal of Physiology-Heart and Circulatory Physiology 2004;286:H2057-64. [DOI: 10.1152/ajpheart.00778.2003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
13 Mizuguchi Y, Specht S, Isse K, Lunz JG, Demetris AJ. Biliary Epithelial Cells. In: Monga SPS, editor. Molecular Pathology of Liver Diseases. Boston: Springer US; 2011. pp. 27-51. [DOI: 10.1007/978-1-4419-7107-4_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Marson FA, Bertuzzo CS, Ribeiro AF, Ribeiro JD. Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: a cross-sectional study. BMC Med Genet 2014;15:27. [PMID: 24593045 DOI: 10.1186/1471-2350-15-27] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
15 Winfield RD, Beierle EA. Pediatric Surgical Issues in Meconium Disease and Cystic Fibrosis. Surgical Clinics of North America 2006;86:317-27. [DOI: 10.1016/j.suc.2005.12.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Férec C, Scotet V, Beucher J, Corvol H. [Genetics and modifier genes, atypical and rare forms]. Arch Pediatr 2012;19 Suppl 1:S3-7. [PMID: 22682487 DOI: 10.1016/S0929-693X(12)71099-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Pirzada O, Taylor C. Modifier genes and cystic fibrosis liver disease. Hepatology;37:714-714. [DOI: 10.1053/jhep.2003.50079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Jonas MM. The role of liver transplantation in cystic fibrosis re-examined. Liver Transpl 2005;11:1463-5. [DOI: 10.1002/lt.20571] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
19 Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004;6:231-9. [DOI: 10.1007/s11894-004-0013-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
20 Collardeau-Frachon S, Bouvier R, Le Gall C, Rivet C, Cabet F, Bellon G, Lachaux A, Scoazec JY. Unexpected diagnosis of cystic fibrosis at liver biopsy: a report of four pediatric cases. Virchows Arch 2007;451:57-64. [PMID: 17554556 DOI: 10.1007/s00428-007-0434-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Gallati S. Disease-modifying genes and monogenic disorders: experience in cystic fibrosis. Appl Clin Genet. 2014;7:133-146. [PMID: 25053892 DOI: 10.2147/tacg.s18675] [Cited by in Crossref: 55] [Cited by in F6Publishing: 28] [Article Influence: 6.9] [Reference Citation Analysis]
22 Ghobadloo SM, Yaghmaei B, Bakayev V, Goudarzi H, Noorinayer B, Rad FH, Samiy S, Aghabozorghi S, Zali MR. GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis. J Gastrointest Surg. 2004;8:423-427. [PMID: 15120366 DOI: 10.1016/j.gassur.2004.02.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
23 Wong A, Cheung B, Nejad C, Gantier M, Graudins A. Hepatotoxicity after paracetamol overdose in a patient with cystic fibrosis despite early acetylcysteine and utility of microRNA to predict hepatotoxicity. Clin Toxicol (Phila) 2018;56:904-6. [PMID: 29564929 DOI: 10.1080/15563650.2018.1454596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Yuan Q, Jonas MM. Pediatric hepatobiliary disease: . Current Opinion in Gastroenterology 2003;19:276-80. [DOI: 10.1097/00001574-200305000-00012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Board PG. The use of glutathione transferase-knockout mice as pharmacological and toxicological models. Expert Opin Drug Metab Toxicol 2007;3:421-33. [PMID: 17539748 DOI: 10.1517/17425255.3.3.421] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
26 Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, Jin L, Zhou C, Fu J, Gao B, Fu Y, Wang FS. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology. 2014;59:1331-1342. [PMID: 24677193 DOI: 10.1002/hep.26916] [Cited by in Crossref: 113] [Cited by in F6Publishing: 115] [Article Influence: 14.1] [Reference Citation Analysis]
27 Flamant C, Henrion-Caude A, Boëlle PY, Brémont F, Brouard J, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Boulé M, Strange RC, Clement A. Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics 2004;14:295-301. [PMID: 15115915 DOI: 10.1097/00008571-200405000-00004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
28 Slieker MG, Sanders EA, Rijkers GT, Ruven HJ, van der Ent CK. Disease modifying genes in cystic fibrosis. Journal of Cystic Fibrosis 2005;4:7-13. [DOI: 10.1016/j.jcf.2005.05.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
29 Zhang M, Wu SQ, He JQ. Are genetic variations in glutathione S-transferases involved in anti-tuberculosis drug-induced liver injury? A meta-analysis. J Clin Pharm Ther 2019;44:844-57. [PMID: 31378997 DOI: 10.1111/jcpt.13006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Bauer M, Herbarth O, Aust G, Hengstler JG, Dotzauer A, Graebsch C, Schmuecking E. Expression patterns and novel splicing variants of glutathione-S-transferase isoenzymes of human lung and hepatocyte cell lines. Cell Tissue Res 2006;324:423-32. [PMID: 16501997 DOI: 10.1007/s00441-005-0150-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
31 Corvol H, Flamant C, Vallet C, Clement A, Brouard J. Les gènes modificateurs dans la mucoviscidose. Archives de Pédiatrie 2006;13:57-63. [DOI: 10.1016/j.arcped.2005.09.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Debray D, Corvol H, Housset C. Modifier genes in cystic fibrosis-related liver disease. Curr Opin Gastroenterol 2019;35:88-92. [PMID: 30585791 DOI: 10.1097/MOG.0000000000000508] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
33 Miyagi SJ, Brown IW, Chock JM, Collier AC. Developmental changes in hepatic antioxidant capacity are age-and sex-dependent. J Pharmacol Sci. 2009;111:440-445. [PMID: 20019448 DOI: 10.1254/jphs.09223sc] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
34 Brind AM, Hurlstone A, Edrisinghe D, Gilmore I, Fisher N, Pirmohamed M, Fryer AA. The role of polymorphisms of glutathione S-transferases GSTM1, M3, P1, T1 and A1 in susceptibility to alcoholic liver disease. Alcohol Alcoholism. 2004;39:478-483. [PMID: 15525789 DOI: 10.1093/alcalc/agh105] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
35 Kelleher T, Staunton M, O'Mahony S, McCormick PA. Advanced hepatocellular carcinoma associated with cystic fibrosis.Eur J Gastroenterol Hepatol. 2005;17:1123-1124. [PMID: 16148560 DOI: 10.1097/00042737-200510000-00018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
36 Kitteringham NR, Palmer L, Owen A, Lian LY, Jenkins R, Dowdall S, Gilmore I, Park BK, Goldring CE. Detection and biochemical characterisation of a novel polymorphism in the human GSTP1 gene. Biochim Biophys Acta 2007;1770:1240-7. [PMID: 17560037 DOI: 10.1016/j.bbagen.2007.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-83. [PMID: 19738092 DOI: 10.1001/jama.2009.1295] [Cited by in Crossref: 189] [Cited by in F6Publishing: 149] [Article Influence: 14.5] [Reference Citation Analysis]
38 Dray X, Hubert D, Munck A, Moreau J, Marteau P. [Digestive complications in adults with cystic fibrosis]. Gastroenterol Clin Biol 2005;29:1279-85. [PMID: 16518288 DOI: 10.1016/s0399-8320(05)82222-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Collaco JM, Cutting GR. Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med 2008;14:559-66. [PMID: 18812833 DOI: 10.1097/MCP.0b013e3283121cdc] [Cited by in Crossref: 88] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
40 Feuillet-fieux M, Nguyen-khoa T, Loriot M, Kelly M, de Villartay P, Sermet I, Verrier P, Bonnefont J, Beaune P, Lenoir G, Lacour B. Glutathione S-transferases related to P. aeruginosa lung infection in cystic fibrosis children: Preliminary study. Clinical Biochemistry 2009;42:57-63. [DOI: 10.1016/j.clinbiochem.2008.09.116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
41 Wu S, Wang YJ, Tang X, Wang Y, Wu J, Ji G, Zhang M, Chen G, Liu Q, Sandford AJ, He JQ. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity. PLoS One. 2016;11:e0157478. [PMID: 27281183 DOI: 10.1371/journal.pone.0157478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
42 Mohammadzadeh Ghobadloo S, Yaghmaei B, Allameh A, Hassani P, Noorinayer B, Zali MR. Polymorphisms of glutathione S-transferase M1, T1, and P1 in patients with HBV-related liver cirrhosis, chronic hepatitis, and normal carriers. Clin Biochem. 2006;39:46-49. [PMID: 16316639 DOI: 10.1016/j.clinbiochem.2005.10.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
43 Curry MP, Hegarty JE. The gallbladder and biliary tract in cystic fibrosis. Curr Gastroenterol Rep 2005;7:147-53. [PMID: 15802104 DOI: 10.1007/s11894-005-0053-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
44 Qin XJ, Hai CX, He W, Liang X, Zhang XD, Zhao KT, Chen HL, Liu R. Protection of antioxidants compound of Chinese drug on liver oxidative injury by local 60Co irradiation in rats with tumor. Shijie Huaren Xiaohua Zazhi 2004; 12(9): 2135-2139 [DOI: 10.11569/wcjd.v12.i9.2135] [Reference Citation Analysis]
45 McKone EF, Shao J, Frangolias DD, Keener CL, Shephard CA, Farin FM, Tonelli MR, Pare PD, Sandford AJ, Aitken ML, Kavanagh TJ. Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am J Respir Crit Care Med 2006;174:415-9. [PMID: 16690975 DOI: 10.1164/rccm.200508-1281OC] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]